A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial
Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. Multicenter, double-blind, randomized, controlled trial. 53 adult patients with CK...
Saved in:
| Published in | American journal of kidney diseases Vol. 65; no. 1; pp. 49 - 57 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.01.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated.
Multicenter, double-blind, randomized, controlled trial.
53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients).
Pentoxifylline (400mg/d; n=26) or matching placebo (control; n=27) for 4 months.
Primary outcome: ESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics.
There was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, −0.39 [95%CI, −0.89 to 0.10] IU/kg/wk/g/L; P=0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95%CI, 1.7-13.5] g/L; P=0.01). There was no difference in ESA dose between groups (−20.8 [95%CI, −67.2 to 25.7] IU/kg/wk; P=0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls.
Sample size smaller than planned due to slow recruitment.
Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia. |
|---|---|
| AbstractList | Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated.
Multicenter, double-blind, randomized, controlled trial.
53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients).
Pentoxifylline (400mg/d; n=26) or matching placebo (control; n=27) for 4 months.
Primary outcome: ESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics.
There was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, −0.39 [95%CI, −0.89 to 0.10] IU/kg/wk/g/L; P=0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95%CI, 1.7-13.5] g/L; P=0.01). There was no difference in ESA dose between groups (−20.8 [95%CI, −67.2 to 25.7] IU/kg/wk; P=0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls.
Sample size smaller than planned due to slow recruitment.
Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia. Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated.BACKGROUNDErythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated.Multicenter, double-blind, randomized, controlled trial.STUDY DESIGNMulticenter, double-blind, randomized, controlled trial.53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients).SETTING & PARTICIPANTS53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients).Pentoxifylline (400mg/d; n=26) or matching placebo (control; n=27) for 4 months.INTERVENTIONSPentoxifylline (400mg/d; n=26) or matching placebo (control; n=27) for 4 months.ESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics.PRIMARY OUTCOMEESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics.There was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, -0.39 [95%CI, -0.89 to 0.10] IU/kg/wk/g/L; P=0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95%CI, 1.7-13.5] g/L; P=0.01). There was no difference in ESA dose between groups (-20.8 [95%CI, -67.2 to 25.7] IU/kg/wk; P=0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls.RESULTSThere was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, -0.39 [95%CI, -0.89 to 0.10] IU/kg/wk/g/L; P=0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95%CI, 1.7-13.5] g/L; P=0.01). There was no difference in ESA dose between groups (-20.8 [95%CI, -67.2 to 25.7] IU/kg/wk; P=0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls.Sample size smaller than planned due to slow recruitment.LIMITATIONSSample size smaller than planned due to slow recruitment.Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia.CONCLUSIONSPentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia. Background Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. Study Design Multicenter, double-blind, randomized, controlled trial. Setting & Participants 53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin ≤ 120 g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L] ≥ 1.0 IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005 μg/kg/wk/g/L for darbepoetin-treated patients). Interventions Pentoxifylline (400 mg/d; n = 26) or matching placebo (control; n = 27) for 4 months. Outcomes Primary outcome: ESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics. Results There was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, −0.39 [95% CI, −0.89 to 0.10] IU/kg/wk/g/L; P = 0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95% CI, 1.7-13.5] g/L; P = 0.01). There was no difference in ESA dose between groups (−20.8 [95% CI, −67.2 to 25.7] IU/kg/wk; P = 0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls. Limitations Sample size smaller than planned due to slow recruitment. Conclusions Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia. Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. Multicenter, double-blind, randomized, controlled trial. 53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients). Pentoxifylline (400mg/d; n=26) or matching placebo (control; n=27) for 4 months. ESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics. There was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, -0.39 [95%CI, -0.89 to 0.10] IU/kg/wk/g/L; P=0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95%CI, 1.7-13.5] g/L; P=0.01). There was no difference in ESA dose between groups (-20.8 [95%CI, -67.2 to 25.7] IU/kg/wk; P=0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls. Sample size smaller than planned due to slow recruitment. Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia. |
| Author | Reidlinger, Donna Ferrari, Paolo Perkovic, Vlado Johnson, David W. Scaria, Anish Hawley, Carmel M. Pedagogos, Eugenie Badve, Sunil V. Morrish, Alicia T. Walker, Rowan Vergara, Liza A. Pascoe, Elaine M. McDonald, Stephen P. Cass, Alan Dalziel, Kim Clarke, Philip |
| Author_xml | – sequence: 1 givenname: David W. surname: Johnson fullname: Johnson, David W. email: david.johnson2@health.qld.gov.au organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 2 givenname: Elaine M. surname: Pascoe fullname: Pascoe, Elaine M. organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 3 givenname: Sunil V. surname: Badve fullname: Badve, Sunil V. organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 4 givenname: Kim surname: Dalziel fullname: Dalziel, Kim organization: Center for Health Policy, Programs & Economics, University of Melbourne, Melbourne, Australia – sequence: 5 givenname: Alan surname: Cass fullname: Cass, Alan organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 6 givenname: Philip surname: Clarke fullname: Clarke, Philip organization: Center for Health Policy, Programs & Economics, University of Melbourne, Melbourne, Australia – sequence: 7 givenname: Paolo surname: Ferrari fullname: Ferrari, Paolo organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 8 givenname: Stephen P. surname: McDonald fullname: McDonald, Stephen P. organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 9 givenname: Alicia T. surname: Morrish fullname: Morrish, Alicia T. organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 10 givenname: Eugenie surname: Pedagogos fullname: Pedagogos, Eugenie organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 11 givenname: Vlado surname: Perkovic fullname: Perkovic, Vlado organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 12 givenname: Donna surname: Reidlinger fullname: Reidlinger, Donna organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 13 givenname: Anish surname: Scaria fullname: Scaria, Anish organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 14 givenname: Rowan surname: Walker fullname: Walker, Rowan organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 15 givenname: Liza A. surname: Vergara fullname: Vergara, Liza A. organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia – sequence: 16 givenname: Carmel M. surname: Hawley fullname: Hawley, Carmel M. organization: Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25115616$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFktFu0zAUhiM0xLrBC3CBfDkkEmwncZJpQqpKoYhJrboiLi3XOVndOXaw02nlOXkgHHVMaBLjyjff__vofOckOjLWQBS9JjghOE_fbxOxvakTikmWYJZgip9FI5LTNGZlWh5FI0wLGrO0ZMfRifdbjHGVMvYiOqY5ITkjbBT9GqOlMLVt1U-o36GFFhLWNp5Y0zurNdRo5ZTQyDZoAaa3d6rZa60MIGvQ1O37jbOdVeCVj6961e606JW5RuPrQKPZvrMOfGeNV7dgwHukDBobaJVEi0AGyKPvqt-gydeP52i1ATQL4-ih4q_2UImWwx-9MBIOgfldF9IP45zNpsv528O0L6PnjdAeXt2_p9G3T9PVZBZfzj9_mYwvY5mntI8lLsi6ACoykTZQYwwNZVVGy7zMBM0KXIimLoqizHIm5LqsIMelyNc5qSU0ZZ6eRmeH3s7ZHzvwPW-Vl6C1MGB3nhOWVllVVWkR0Df36G7dQs07p1rh9vyPiQDQAyCd9d5B84AQzAfdfMsH3XzQzTHjQXcIlY9CUvVhrYM9ofTT0YtDFMKCbhU47mXQIaFWDmTPa6uejn94FJdBg5JC38Ae_NbunAmr54R7yjG_Gk5xuESShSMsCxIKzv9d8L_ffwPNn_IH |
| CitedBy_id | crossref_primary_10_1016_j_medcli_2024_09_032 crossref_primary_10_1111_nep_12815 crossref_primary_10_1186_s40697_015_0066_5 crossref_primary_10_1159_000516901 crossref_primary_10_1371_journal_pone_0134104 crossref_primary_10_3390_kidneydial2030040 crossref_primary_10_1111_jorc_12324 crossref_primary_10_1159_000441583 crossref_primary_10_1179_1351000215Y_0000000022 crossref_primary_10_3390_ph15091063 crossref_primary_10_2169_naika_104_1414 crossref_primary_10_1002_14651858_CD008176_pub3 crossref_primary_10_1111_sdi_12379 crossref_primary_10_3390_toxins16110463 crossref_primary_10_1002_cpt_173 crossref_primary_10_1016_j_bja_2020_01_001 crossref_primary_10_1016_j_ekir_2018_02_009 crossref_primary_10_1177_0300060516663094 crossref_primary_10_12688_f1000research_21374_1 crossref_primary_10_1016_j_xkme_2020_06_008 crossref_primary_10_1111_jcpt_13696 crossref_primary_10_1371_journal_pone_0172735 crossref_primary_10_1007_s10157_019_01767_w |
| Cites_doi | 10.1111/j.1440-1797.2009.01203.x 10.1053/j.ajkd.2004.08.002 10.1093/ndt/gfk011 10.1182/blood-2002-10-3235 10.1053/j.ajkd.2008.12.040 10.1111/j.1440-1797.2010.01407.x 10.1126/science.1104742 10.1093/ndt/gfm579 10.1186/1471-2369-9-8 10.1053/j.ajkd.2004.08.042 10.1056/NEJMoa1005109 10.4103/1319-2442.124492 10.1186/1471-2369-14-67 10.1172/JCI200420945 10.1093/ndt/gfh1060 10.1073/pnas.0409808102 10.1093/ndt/17.suppl_11.39 10.1074/jbc.M008922200 10.1056/NEJMoa0907845 10.1097/01.ASN.0000131523.17045.56 10.1093/ndt/gfq802 10.1111/j.1440-1797.2004.00261.x 10.5455/medarh.2012.66.84-86 10.1111/j.1440-1797.2007.00810.x 10.7326/0003-4819-153-1-201007060-00252 10.1097/00005650-199206000-00002 10.1080/003655999750016113 10.1185/030079904X2763 |
| ContentType | Journal Article |
| Copyright | 2014 Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2014 – notice: Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved. |
| CorporateAuthor | HERO Study Collaborative Group |
| CorporateAuthor_xml | – name: HERO Study Collaborative Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1053/j.ajkd.2014.06.020 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1523-6838 |
| EndPage | 57 |
| ExternalDocumentID | 25115616 10_1053_j_ajkd_2014_06_020 S0272638614009871 1_s2_0_S0272638614009871 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 23M 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AAFWJ AALRI AAQFI AAQQT AAQXK AAWTL AAXUO AAYWO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO ADVLN AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGHFR AGQPQ AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BELOY CAG COF CS3 EBS EFJIC EFKBS EJD EX3 F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ J5H K-O KOM L7B M41 MO0 N4W O9- OE- P2P PC. PI~ R2- ROL SEL SES SJN SSZ TWZ UNMZH WOW X7M XH2 YCW Z5R ZGI ZXP AAYOK ADPAM AFCTW AAIAV AGZHU AHPSJ ALXNB ZA5 AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c532t-c071b7e2a4a3fed00ef269428584a24707afd7778456acb89e508a5b51dcef853 |
| ISSN | 0272-6386 1523-6838 |
| IngestDate | Thu Jul 10 19:11:57 EDT 2025 Thu Apr 03 07:04:21 EDT 2025 Thu Apr 24 23:06:42 EDT 2025 Tue Jul 01 03:03:45 EDT 2025 Fri Feb 23 02:34:55 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Aug 26 19:56:36 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | dialysis drug sensitivity Anemia ESA hyporesponsiveness chronic kidney disease (CKD) hemoglobin randomized controlled trial erythropoiesis-stimulating agent (ESA) epoetin pentoxifylline darbepoetin ESA resistance index (ERI) erythropoietin |
| Language | English |
| License | Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c532t-c071b7e2a4a3fed00ef269428584a24707afd7778456acb89e508a5b51dcef853 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 25115616 |
| PQID | 1639499937 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1639499937 pubmed_primary_25115616 crossref_primary_10_1053_j_ajkd_2014_06_020 crossref_citationtrail_10_1053_j_ajkd_2014_06_020 elsevier_sciencedirect_doi_10_1053_j_ajkd_2014_06_020 elsevier_clinicalkeyesjournals_1_s2_0_S0272638614009871 elsevier_clinicalkey_doi_10_1053_j_ajkd_2014_06_020 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-01-01 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – month: 01 year: 2015 text: 2015-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of kidney diseases |
| PublicationTitleAlternate | Am J Kidney Dis |
| PublicationYear | 2015 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Bock, Hirt-Minkowski, Brunisholz (bib32) 2008; 23 Mohammadpour, Nazemian, Khaiat (bib18) 2014; 25 Discount Chemist Warehouse. Search results. Semmler, Gebert, Eisenhut (bib15) 1993; 78 Solomon, Uno, Lewis (bib6) 2010; 363 Johnson, Hawley, Rosser (bib20) 2008; 9 Badve, Hawley, Johnson (bib3) 2011; 16 Navarro, Mora, Garcia (bib19) 1999; 33 Park, Valore, Waring, Ganz (bib14) 2001; 276 Ferrari, Mallon, Trinder, Olynyk (bib17) 2010; 15 Zhang, Thamer, Stefanik, Kaufman, Cotter (bib5) 2004; 44 Badve, Beller, Cass (bib8) 2013; 8 Australian Government Department of Health. Pharmaceutical benefits scheme. Neuner, Klosner, Schauer (bib9) 1994; 83 Macdougall, Cooper (bib7) 2002; 17 Cooper, Mikhail, Lethbridge, Kemeny, Macdougall (bib16) 2004; 15 Macdougall (bib28) 2004; 19 Johnson, Pollock, Macdougall (bib2) 2007; 12 Accessed September 17, 2013. Panichi, Rosati, Bigazzi (bib31) 2011; 26 Nemeth, Tuttle, Powelson (bib12) 2004; 306 McClellan, Aronoff, Bolton (bib1) 2004; 20 Palmer, Navaneethan, Craig (bib22) 2010; 153 Kausz, Solid, Pereira, Collins, St Peter (bib4) 2005; 45 Nemeth, Valore, Territo, Schiller, Lichtenstein, Ganz (bib13) 2003; 101 Roger, Cooper (bib23) 2004; 9 Mortazavi, Seyrafian, Taheri (bib27) 2012; 66 Lee, Peng, Gelbart, Wang, Beutler (bib10) 2005; 102 Ware, Sherbourne (bib24) 1992; 30 Locatelli, Andrulli, Memoli (bib29) 2006; 21 Schneider, Schneider, Scharnagl, Jardine, Wanner, Drechsler (bib30) 2013; 14 Pfeffer, Burdmann, Chen (bib21) 2009; 361 Kalantar-Zadeh, Lee, Miller (bib33) 2009; 53 Nemeth, Rivera, Gabayan (bib11) 2004; 113 Ware (10.1053/j.ajkd.2014.06.020_bib24) 1992; 30 Neuner (10.1053/j.ajkd.2014.06.020_bib9) 1994; 83 Bock (10.1053/j.ajkd.2014.06.020_bib32) 2008; 23 Zhang (10.1053/j.ajkd.2014.06.020_bib5) 2004; 44 Nemeth (10.1053/j.ajkd.2014.06.020_bib13) 2003; 101 Nemeth (10.1053/j.ajkd.2014.06.020_bib12) 2004; 306 Nemeth (10.1053/j.ajkd.2014.06.020_bib11) 2004; 113 Cooper (10.1053/j.ajkd.2014.06.020_bib16) 2004; 15 Palmer (10.1053/j.ajkd.2014.06.020_bib22) 2010; 153 Mortazavi (10.1053/j.ajkd.2014.06.020_bib27) 2012; 66 Park (10.1053/j.ajkd.2014.06.020_bib14) 2001; 276 Navarro (10.1053/j.ajkd.2014.06.020_bib19) 1999; 33 10.1053/j.ajkd.2014.06.020_bib26 10.1053/j.ajkd.2014.06.020_bib25 Kalantar-Zadeh (10.1053/j.ajkd.2014.06.020_bib33) 2009; 53 Badve (10.1053/j.ajkd.2014.06.020_bib3) 2011; 16 Pfeffer (10.1053/j.ajkd.2014.06.020_bib21) 2009; 361 Ferrari (10.1053/j.ajkd.2014.06.020_bib17) 2010; 15 Badve (10.1053/j.ajkd.2014.06.020_bib8) 2013; 8 Lee (10.1053/j.ajkd.2014.06.020_bib10) 2005; 102 Macdougall (10.1053/j.ajkd.2014.06.020_bib28) 2004; 19 Roger (10.1053/j.ajkd.2014.06.020_bib23) 2004; 9 Macdougall (10.1053/j.ajkd.2014.06.020_bib7) 2002; 17 Johnson (10.1053/j.ajkd.2014.06.020_bib2) 2007; 12 Solomon (10.1053/j.ajkd.2014.06.020_bib6) 2010; 363 Mohammadpour (10.1053/j.ajkd.2014.06.020_bib18) 2014; 25 Semmler (10.1053/j.ajkd.2014.06.020_bib15) 1993; 78 Kausz (10.1053/j.ajkd.2014.06.020_bib4) 2005; 45 Johnson (10.1053/j.ajkd.2014.06.020_bib20) 2008; 9 Locatelli (10.1053/j.ajkd.2014.06.020_bib29) 2006; 21 Panichi (10.1053/j.ajkd.2014.06.020_bib31) 2011; 26 Schneider (10.1053/j.ajkd.2014.06.020_bib30) 2013; 14 McClellan (10.1053/j.ajkd.2014.06.020_bib1) 2004; 20 |
| References_xml | – volume: 113 start-page: 1271 year: 2004 end-page: 1276 ident: bib11 article-title: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin publication-title: J Clin Invest – volume: 16 start-page: 144 year: 2011 end-page: 153 ident: bib3 article-title: Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? publication-title: Nephrology – volume: 12 start-page: 321 year: 2007 end-page: 330 ident: bib2 article-title: Erythropoiesis-stimulating agent hyporesponsiveness publication-title: Nephrology – volume: 26 start-page: 2641 year: 2011 end-page: 2648 ident: bib31 article-title: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study publication-title: Nephrol Dial Transplant – volume: 20 start-page: 1501 year: 2004 end-page: 1510 ident: bib1 article-title: The prevalence of anemia in patients with chronic kidney disease publication-title: Curr Med Res Opin – volume: 276 start-page: 7806 year: 2001 end-page: 7810 ident: bib14 article-title: Hepcidin, a urinary antimicrobial peptide synthesized in the liver publication-title: J Biol Chem – volume: 153 start-page: 23 year: 2010 end-page: 33 ident: bib22 article-title: Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease publication-title: Ann Intern Med – volume: 102 start-page: 1906 year: 2005 end-page: 1910 ident: bib10 article-title: Regulation of hepcidin transcription by interleukin-1 and interleukin-6 publication-title: Proc Natl Acad Sci U S A – volume: 101 start-page: 2461 year: 2003 end-page: 2463 ident: bib13 article-title: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein publication-title: Blood – volume: 9 start-page: 8 year: 2008 ident: bib20 article-title: Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial publication-title: BMC Nephrol – volume: 8 start-page: CD006861 year: 2013 ident: bib8 article-title: Interventions for erythropoietin-resistant anaemia in dialysis patients publication-title: Cochrane Database Syst Rev – volume: 14 start-page: 67 year: 2013 ident: bib30 article-title: Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes publication-title: BMC Nephrol – volume: 15 start-page: 344 year: 2010 end-page: 349 ident: bib17 article-title: Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease publication-title: Nephrology – volume: 44 start-page: 866 year: 2004 end-page: 876 ident: bib5 article-title: Epoetin requirements predict mortality in hemodialysis patients publication-title: Am J Kidney Dis – volume: 66 start-page: 84 year: 2012 end-page: 86 ident: bib27 article-title: Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial publication-title: Med Arhiv – volume: 306 start-page: 2090 year: 2004 end-page: 2093 ident: bib12 article-title: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization publication-title: Science – volume: 361 start-page: 2019 year: 2009 end-page: 2032 ident: bib21 article-title: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease publication-title: N Engl J Med – volume: 9 start-page: 223 year: 2004 end-page: 228 ident: bib23 article-title: What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? publication-title: Nephrology – volume: 33 start-page: 121 year: 1999 end-page: 125 ident: bib19 article-title: Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure publication-title: Scand J Urol Nephrol – reference: . Accessed September 17, 2013. – volume: 83 start-page: 262 year: 1994 end-page: 267 ident: bib9 article-title: Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells publication-title: Immunology – volume: 25 start-page: 73 year: 2014 end-page: 78 ident: bib18 article-title: Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients publication-title: Saudi J Kidney Dis Transplant – volume: 30 start-page: 473 year: 1992 end-page: 483 ident: bib24 article-title: The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection publication-title: Med Care – volume: 53 start-page: 823 year: 2009 end-page: 834 ident: bib33 article-title: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients publication-title: Am J Kidney Dis – reference: Discount Chemist Warehouse. Search results. – volume: 15 start-page: 1877 year: 2004 end-page: 1882 ident: bib16 article-title: Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure publication-title: J Am Soc Nephrol – volume: 19 start-page: V73 year: 2004 end-page: V78 ident: bib28 article-title: Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients? publication-title: Nephrol Dial Transplant – volume: 23 start-page: 301 year: 2008 end-page: 308 ident: bib32 article-title: Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta publication-title: Nephrol Dial Transplant – volume: 21 start-page: 991 year: 2006 end-page: 998 ident: bib29 article-title: Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients publication-title: Nephrol Dial Transplant – volume: 78 start-page: 520 year: 1993 end-page: 525 ident: bib15 article-title: Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity publication-title: Immunology – reference: Australian Government Department of Health. Pharmaceutical benefits scheme. – volume: 363 start-page: 1146 year: 2010 end-page: 1155 ident: bib6 article-title: Erythropoietic response and outcomes in kidney disease and type 2 diabetes publication-title: N Engl J Med – volume: 17 start-page: 39 year: 2002 end-page: 43 ident: bib7 article-title: Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines publication-title: Nephrol Dial Transplant – volume: 45 start-page: 136 year: 2005 end-page: 147 ident: bib4 article-title: Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? publication-title: Am J Kidney Dis – volume: 15 start-page: 344 issue: 3 year: 2010 ident: 10.1053/j.ajkd.2014.06.020_bib17 article-title: Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease publication-title: Nephrology doi: 10.1111/j.1440-1797.2009.01203.x – volume: 44 start-page: 866 issue: 5 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib5 article-title: Epoetin requirements predict mortality in hemodialysis patients publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2004.08.002 – volume: 21 start-page: 991 issue: 4 year: 2006 ident: 10.1053/j.ajkd.2014.06.020_bib29 article-title: Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfk011 – volume: 101 start-page: 2461 issue: 7 year: 2003 ident: 10.1053/j.ajkd.2014.06.020_bib13 article-title: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein publication-title: Blood doi: 10.1182/blood-2002-10-3235 – volume: 53 start-page: 823 issue: 5 year: 2009 ident: 10.1053/j.ajkd.2014.06.020_bib33 article-title: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2008.12.040 – volume: 83 start-page: 262 issue: 2 year: 1994 ident: 10.1053/j.ajkd.2014.06.020_bib9 article-title: Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells publication-title: Immunology – volume: 16 start-page: 144 issue: 2 year: 2011 ident: 10.1053/j.ajkd.2014.06.020_bib3 article-title: Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? publication-title: Nephrology doi: 10.1111/j.1440-1797.2010.01407.x – volume: 306 start-page: 2090 issue: 5704 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib12 article-title: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization publication-title: Science doi: 10.1126/science.1104742 – volume: 23 start-page: 301 issue: 1 year: 2008 ident: 10.1053/j.ajkd.2014.06.020_bib32 article-title: Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfm579 – volume: 9 start-page: 8 year: 2008 ident: 10.1053/j.ajkd.2014.06.020_bib20 article-title: Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial publication-title: BMC Nephrol doi: 10.1186/1471-2369-9-8 – volume: 45 start-page: 136 issue: 1 year: 2005 ident: 10.1053/j.ajkd.2014.06.020_bib4 article-title: Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2004.08.042 – volume: 363 start-page: 1146 issue: 12 year: 2010 ident: 10.1053/j.ajkd.2014.06.020_bib6 article-title: Erythropoietic response and outcomes in kidney disease and type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1005109 – volume: 25 start-page: 73 issue: 1 year: 2014 ident: 10.1053/j.ajkd.2014.06.020_bib18 article-title: Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients publication-title: Saudi J Kidney Dis Transplant doi: 10.4103/1319-2442.124492 – volume: 14 start-page: 67 year: 2013 ident: 10.1053/j.ajkd.2014.06.020_bib30 article-title: Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes publication-title: BMC Nephrol doi: 10.1186/1471-2369-14-67 – volume: 113 start-page: 1271 issue: 9 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib11 article-title: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin publication-title: J Clin Invest doi: 10.1172/JCI200420945 – volume: 19 start-page: V73 issue: suppl 5 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib28 article-title: Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients? publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfh1060 – volume: 102 start-page: 1906 issue: 6 year: 2005 ident: 10.1053/j.ajkd.2014.06.020_bib10 article-title: Regulation of hepcidin transcription by interleukin-1 and interleukin-6 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0409808102 – volume: 17 start-page: 39 issue: suppl 11 year: 2002 ident: 10.1053/j.ajkd.2014.06.020_bib7 article-title: Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/17.suppl_11.39 – volume: 276 start-page: 7806 issue: 11 year: 2001 ident: 10.1053/j.ajkd.2014.06.020_bib14 article-title: Hepcidin, a urinary antimicrobial peptide synthesized in the liver publication-title: J Biol Chem doi: 10.1074/jbc.M008922200 – volume: 361 start-page: 2019 issue: 21 year: 2009 ident: 10.1053/j.ajkd.2014.06.020_bib21 article-title: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease publication-title: N Engl J Med doi: 10.1056/NEJMoa0907845 – volume: 15 start-page: 1877 issue: 7 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib16 article-title: Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000131523.17045.56 – ident: 10.1053/j.ajkd.2014.06.020_bib25 – volume: 26 start-page: 2641 issue: 8 year: 2011 ident: 10.1053/j.ajkd.2014.06.020_bib31 article-title: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfq802 – volume: 9 start-page: 223 issue: 4 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib23 article-title: What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? publication-title: Nephrology doi: 10.1111/j.1440-1797.2004.00261.x – volume: 66 start-page: 84 issue: 2 year: 2012 ident: 10.1053/j.ajkd.2014.06.020_bib27 article-title: Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial publication-title: Med Arhiv doi: 10.5455/medarh.2012.66.84-86 – ident: 10.1053/j.ajkd.2014.06.020_bib26 – volume: 12 start-page: 321 issue: 4 year: 2007 ident: 10.1053/j.ajkd.2014.06.020_bib2 article-title: Erythropoiesis-stimulating agent hyporesponsiveness publication-title: Nephrology doi: 10.1111/j.1440-1797.2007.00810.x – volume: 153 start-page: 23 issue: 1 year: 2010 ident: 10.1053/j.ajkd.2014.06.020_bib22 article-title: Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease publication-title: Ann Intern Med doi: 10.7326/0003-4819-153-1-201007060-00252 – volume: 30 start-page: 473 issue: 6 year: 1992 ident: 10.1053/j.ajkd.2014.06.020_bib24 article-title: The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection publication-title: Med Care doi: 10.1097/00005650-199206000-00002 – volume: 33 start-page: 121 issue: 2 year: 1999 ident: 10.1053/j.ajkd.2014.06.020_bib19 article-title: Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure publication-title: Scand J Urol Nephrol doi: 10.1080/003655999750016113 – volume: 78 start-page: 520 issue: 4 year: 1993 ident: 10.1053/j.ajkd.2014.06.020_bib15 article-title: Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity publication-title: Immunology – volume: 8 start-page: CD006861 year: 2013 ident: 10.1053/j.ajkd.2014.06.020_bib8 article-title: Interventions for erythropoietin-resistant anaemia in dialysis patients publication-title: Cochrane Database Syst Rev – volume: 20 start-page: 1501 issue: 9 year: 2004 ident: 10.1053/j.ajkd.2014.06.020_bib1 article-title: The prevalence of anemia in patients with chronic kidney disease publication-title: Curr Med Res Opin doi: 10.1185/030079904X2763 |
| SSID | ssj0009366 |
| Score | 2.31007 |
| Snippet | Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for... Background Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 49 |
| SubjectTerms | Adult Aged Anemia Anemia - blood Anemia - drug therapy Anemia - etiology chronic kidney disease (CKD) Cost Savings darbepoetin dialysis Double-Blind Method Drug Monitoring - methods Drug Resistance - drug effects drug sensitivity Drug Synergism epoetin Erythropoiesis - drug effects erythropoiesis-stimulating agent (ESA) erythropoietin Erythropoietin - administration & dosage Erythropoietin - adverse effects ESA hyporesponsiveness ESA resistance index (ERI) Hematologic Agents - administration & dosage Hematologic Agents - adverse effects hemoglobin Hemoglobins - analysis Humans Middle Aged Nephrology pentoxifylline Pentoxifylline - administration & dosage Pentoxifylline - adverse effects Quality of Life randomized controlled trial Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - economics Renal Insufficiency, Chronic - psychology Vasodilator Agents - administration & dosage Vasodilator Agents - adverse effects |
| Title | A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0272638614009871 https://www.clinicalkey.es/playcontent/1-s2.0-S0272638614009871 https://dx.doi.org/10.1053/j.ajkd.2014.06.020 https://www.ncbi.nlm.nih.gov/pubmed/25115616 https://www.proquest.com/docview/1639499937 |
| Volume | 65 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db5swELe6VJr2Mm3rPrIvedIeNmVkYCDA3tI2W7Qu69SmH2_IgJFoCVRNMjX5O_cH7Q4bSJam2_qCEsDY6H7Yd-ff3RHyVsSeDcuuo0WMB5oF92iB2zE0z8V8aS4XMpB28L3TP7K-ntqnG3e2FlhL00nQDufXxpXcRqpwDuSKUbL_IdnqoXACfoN84QgShuM_ybjbOuBZlI-SuXRZ_kCfeJBrO5J_noIyOSyqciDRDVaX_CqJZ2mhWILQe5czWSQBjOVkrB1OklFRywv9JBhw1erPQDlXHFo1J6J3JJN8epmQFfmzGMa0t1vyN_qYtwEfsvB8eChuFKCuihNJ0WT_6qJgKqkBgabb7x3so5eiGPOi1lxtKy3kuThPogzmM7XBVBMhZcWviq7fOmnXu2TjUBIfeynHLgfVpW0e_VQkpSxJW8fVhV2ezhNJZNhLRosuEsP-w0VSxe4sUUvBHmcazD4qEbea_pmpdVyZb6ZcH2Qti6XvQE72MteqUhtkmu2VBUkvqoqctfnZOealNawiWyzT6-W3IkUe4ohwQGDz6p6LiRE2GRg_rEE2v2x_O-7WyaRNuQdfvoEKBoO-Pq72tE7hWmdQFYrV8AG5rywi2pXwfkg2RPaI3B0ozscW-dWlNco_0FWM0wIvNI_pMsZpntH1GKcFxukqxmmSUYlxWmKcImApYPwTBYTTEuF0GeG0RrhssIxw-g7x_V6O9jE5-twb7vQ1VYtEC22TTbQQVPHAEYxb3IxFpOsixhhw5oICz5nl6A6PI8dxXDBIeBi4ngDLh9uBbUShiEEnfkIaWZ6JZ4QKF_5HAjNPWiBp4cVmGNpeJ-JmaLum0SRGKTA_VIn6sV5M6heEEdsEgx2F7KOQfaSlMr1JWlWbC5mm5sa7zRIHfhmADSqDD6C9sZVzXSsxVt_-2Df8MfN1fwXITWJXLZViLxX2v_b4pgSpD6sebmXyTORT6AkMK_TVmE6TPJXord4bnSZgFXae37LXF-RePYm8JI3J5VS8AstjErxWH-Jv2XI0qw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Randomized%2C+Placebo-Controlled+Trial+of+Pentoxifylline+on+Erythropoiesis-Stimulating+Agent+Hyporesponsiveness+in+Anemic+Patients+With+CKD%3A+The+Handling+Erythropoietin+Resistance+With+Oxpentifylline+%28HERO%29+Trial&rft.jtitle=American+journal+of+kidney+diseases&rft.au=Johnson%2C+David+W.&rft.au=Pascoe%2C+Elaine+M.&rft.au=Badve%2C+Sunil+V.&rft.au=Dalziel%2C+Kim&rft.date=2015-01-01&rft.pub=Elsevier+Inc&rft.issn=0272-6386&rft.eissn=1523-6838&rft.volume=65&rft.issue=1&rft.spage=49&rft.epage=57&rft_id=info:doi/10.1053%2Fj.ajkd.2014.06.020&rft.externalDocID=S0272638614009871 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F02726386%2FS0272638613X00277%2Fcov150h.gif |